We are live on ! Find out more
ZVSA icon

ZyVersa Therapeutics

Delisted

ZVSA was delisted on the 16th of July, 2025.

5 hedge funds and large institutions have $273K invested in ZyVersa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

616% more capital inflows, than outflows

Capital inflows: $165K | Capital outflows: $23K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

150% more funds holding

Funds holding: 2 → 5 (+3)

0.69% more ownership

Funds ownership: 0.87% → 1.56% (+0.69%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ZVSA Hedge Fund Activity: Q1 2023 in Review

5 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q1 2023, worth a combined $273K — up 121% from $124K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ZVSA positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $83.8K. The largest seller was CSS LLC, exiting entirely with an estimated $23K sold.

  • 5 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q1 2023, up from 2 in Q4 2022.
  • Funds reported $273K of ZyVersa Therapeutics stock for Q1 2023, up 121% quarter-over-quarter.
  • 4 funds opened new ZyVersa Therapeutics positions in Q1 2023 and 1 closed out, a net change of +3 holders.
  • The largest ZyVersa Therapeutics buyer in Q1 2023 was Goldman Sachs, an estimated $83.8K added.
  • The largest ZyVersa Therapeutics seller in Q1 2023 was CSS LLC, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2023.